Fundraising Fox

Artica Therapeutics

Founded 2020 · 19 employees on LinkedIn · 7 known investors

Find your way into Artica Therapeutics

296 people in our graph share verified history with the Artica Therapeutics team — schools, employers, funds. One of them is your warm intro.

Alan Ezekowitzunlockedknows Tjeerd Barf · together at MSD / Organon (overlapped)
×6knows the team · via MSD / Organon
knows the team · via Astellas Pharma
×4knows the team · via University of Groningen

Artica Therapeutics develops orally bioavailable small molecule inhibitors that use covalent chemistry to achieve antibody-like efficacy, positioned as an "antibody-in-a-pill" approach. The company targets severe autoimmune and inflammatory disorders for patients with immune-mediated conditions.

BiotechDeep TechHealthtech

Founders & leadership

Artica Therapeutics was founded in 2020 by Tjeerd Barf, Arwin Ridder, and Ad IJzerman.

TBTjeerd Barf
Tjeerd BarfinCo-founder & CEOTjeerd Barf brings over 25 years of pharmaceutical research and development experience across startup and large-cap organizations, with expertise in metabolic disease, immunology, and oncology. He specializes in covalent chemistry drug discovery, medicinal chemistry, and structure-based drug design for kinase and protease targets.
ARArwin Ridder
Arwin RidderinCo-founder & COOArwin Ridder is co-founder and COO of Artica Therapeutics, which develops small molecule inhibitors for autoimmune and inflammatory conditions. He has worked as a drug developer and project leader on complex pharmaceutical programs.
AI
Ad IJzermaninCo-founder & SAB Chair
JJason
JasoninChief Scientific Officer

Investors · 7

BioGeneration Ventures✓ verifiedNaarden
Thuja Capital✓ verifiedUtrecht
Seroba Life SciencesDublin · $540K – $7.6M
BGVreportedSilicon Valley

Also in the syndicate · 3

Innovation QuarterInnovationQuarterSerobalead

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Artica Therapeutics Appoints Piet Wigerinck to its Board of Directors | BioGeneration Venturesbiogenerationventures.com · Mar 2024Biotechnology Company Artica Therapeutics Secures €12M in Seed Fundingstartuprise.co.uk · Nov 2023Dutch-based Artica Therapeutics bags €12M to help patients suffering from autoimmune and inflammatory disorders - Silicon Canalssiliconcanals.com · Nov 2023Artica Therapeutics closes €12M Seed Investment to develop covalent therapeutics for Autoimmune and Inflammatory Disorders | BioGeneration Venturesbiogenerationventures.com · Nov 2023Artica Therapeutics | BioGeneration Venturesbiogenerationventures.com

Frequently asked questions

What does Artica Therapeutics do?
Artica Therapeutics develops orally bioavailable small molecule inhibitors that use covalent chemistry to achieve antibody-like efficacy, positioned as an "antibody-in-a-pill" approach. The company targets severe autoimmune and inflammatory disorders for patients with immune-mediated conditions.
Who founded Artica Therapeutics?
Artica Therapeutics was founded by Tjeerd Barf, Arwin Ridder, Ad IJzerman in 2020.
Who are Artica Therapeutics's investors?
Artica Therapeutics's investors include BioGeneration Ventures, Thuja Capital, Seroba Life Sciences, BGV.